MedTrace Logo

Role of Bumetanide in Treatment of Autism

NCT04766177 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2021-02-23

No results posted yet for this study

Summary

Role of bumetanide in Autism

Conditions

Interventions

DRUG

Bumetanide

bumetanide 0.5 mg twice daily

DRUG

Placebo

placebo tablets twice daily

Sponsors & Collaborators

  • Sherief Abd-Elsalam

    lead OTHER

Principal Investigators

  • Osama Elagamy, Prof · Pediatrics Department- Kafr-Elsheikh University

  • Abeer Salamah, Dr · Pediatrics Department- Kafr-Elsheikh University

  • Esraa Shaker, Msc · Pediatrics Department- Kafr-Elsheikh University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2030-12-01
Completion
2030-12-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04766177 on ClinicalTrials.gov